Resurgence of Pseudomonas Endocarditis in Detroit, 2006-2008

被引:45
作者
Reyes, Milagros P. [1 ,2 ]
Ali, Ammar [2 ]
Mendes, Rodrigo E. [3 ]
Biedenbach, Douglas J. [3 ]
机构
[1] Wayne State Univ, Harper Univ Hosp, Div Infect Dis, Dept Med, Detroit, MI 48201 USA
[2] Henry Ford Hlth Syst, Div Infect Dis, Detroit, MI USA
[3] JMI Labs, N Liberty, IA USA
关键词
LEFT-SIDED ENDOCARDITIS; INFECTIVE ENDOCARDITIS; CONTINUOUS-INFUSION; MEDICAL-CENTER; TRICUSPID VALVULECTOMY; NARCOTIC ADDICTS; BETA-LACTAMS; AERUGINOSA; THERAPY; TOBRAMYCIN;
D O I
10.1097/MD.0b013e3181b8bedc
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A resurgence of endocarditis due to Pseudomonas aeruginosa was seen in 10 injection drug users (IDUs) in Detroit between 2006 and 2008 (6 men, 4 women; mean age, 48.1 yr). All patients tested negative for the human immunodeficiency virus (HIV). Five patients had left-sided endocarditis of the mitral valve and/or the aortic valve; 3 of 5 patients had prosthetic valve endocarditis. Four of 10 patients had right-sided endocarditis of the tricuspid valve alone. One patient had bilateral involvement of the aortic and tricuspid valves. Nine patients had Pseudomonas endocarditis (PsE); 1 patient had mixed endocarditis with P. aeruginosa and Candida parapsilosis. Seven of 10 patients were treated with a combination of intravenous cefepime, 4-6 g/d. plus high-dose tobramycin (HDT) for at least 6 weeks. Tobramycin, 8 mg/kg per day, was given as a single daily dose intravenously, aiming for peak serum levels of 18-22 mu g/mL and trough levels of < 11 mu g/mL. The patient with mixed endocarditis was also treated with fluconazole. Two patients initially treated with other antipseudomonal regimens, including cefepime alone and piperacillin/tazobactam plus tobramycin, failed treatment and were switched to cefepime and HDT A third patient was switched to cefepime and ciprofloxacin because of nephrotoxicity. Two patients developed nephrotoxicity to tobramycin; 1 patient developed ototoxicity. The overall medical cure rate for both left-sided and right-sided disease was 80% (4/5). All 5 patients who required surgery survived (5/5; 100%). Overall outcome was 90% (9/10). Indications for valve replacement were recurrent Pseudomonas bacteremia (n = 3), recurrent bacteremia and congestive heart failure (n = 1). and persistent bacteremia and fungemia (n = 1). Tricuspid valvulectomy with valve replacement was successful in 2 patients and in a third patient who had successful replacement of both the tricuspid and the aortic valve,for recurrent bacteremia and congestive heart failure. Two patients with pure left-sided prosthetic valve endocarditis underwent successful repeat valve replacements. Although this is a small series, the overall mortality rate (1/10; 10%) was low. The patient who did not survive had left-sided involvement of the aortic valve and Could not undergo surgery because of a large embolic cerebral infarct. The mortality rate of left-sided disease in the current series was 16.7% (1/6 including the patient with tricuspid and aortic valve PsE) compared to 60% in a series of 15 patients reported in 1990. Our current antimicrobial regimen for PsE consists of a combination of cefepime, 6 g/d, in 3 divided doses, plus HDT, 8 mg/kg per day, given as a single daily dose for 6 weeks. For cefepime-resistant Pseudomonas, imipenem, 4-6 g/d, or meropenem, 6 g/d, plus HDT has been successful. For right-sided disease refractory to medical therapy, surgical intervention is recommended if Pseudomonas bacteremia persists for 2 weeks on appropriate antimicrobial therapy or if bacteremia recurs after a 6-week course of treatment. Tricuspid repair/reconstruction or valvulectomy with valve replacement plus combined antipseudomonal regimen may be the optimal therapy for refractory right-sided endocarditis. This approach not only may prevent the development of severe and permanent impairment of right ventricular function, which is a complication of valvulectomy alone without valve replacement, but also may cure the infection. For left-sided disease, surgery is recommended if blood cultures remain positive for 7 days on appropriate antimicrobial therapy or if Pseudomonas bacteremia recurs after completion of a 6-week course of the combined regimen.
引用
收藏
页码:294 / 301
页数:8
相关论文
共 44 条
[1]   PACEMAKER ENDOCARDITIS - REPORT OF 44 CASES AND REVIEW OF THE LITERATURE [J].
ARBER, N ;
PRAS, E ;
COPPERMAN, Y ;
SCHAPIRO, JM ;
MEINER, V ;
LOSSOS, IS ;
MILITIANU, A ;
HASSIN, D ;
PRAS, E ;
SHAI, A ;
MOSHKOWITZ, M ;
SIDI, Y .
MEDICINE, 1994, 73 (06) :299-305
[2]  
ARBULU A, 1981, J THORAC CARDIOV SUR, V82, P684
[3]   TRICUSPID VALVULECTOMY WITHOUT REPLACEMENT - 20 YEARS EXPERIENCE [J].
ARBULU, A ;
HOLMES, RJ ;
ASFAW, I .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1991, 102 (06) :917-922
[4]   LACK OF INVITRO INACTIVATION OF TOBRAMYCIN BY IMIPENEM CILASTATIN [J].
ARIANO, RE ;
KASSUM, DA ;
MEATHERALL, RC ;
PATRICK, WD .
ANNALS OF PHARMACOTHERAPY, 1992, 26 (09) :1075-1077
[5]  
Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564
[6]   SELECTIVE SURVIVAL IN PENTAZOCINE AND TRIPELENNAMINE OF PSEUDOMONAS-AERUGINOSA SEROTYPE-O11 FROM DRUG-ADDICTS [J].
BOTSFORD, KB ;
WEINSTEIN, RA ;
NATHAN, CR ;
KABINS, SA .
JOURNAL OF INFECTIOUS DISEASES, 1985, 151 (02) :209-216
[7]  
CABELL CH, 2003, 7 INT S MOD CONC END
[8]  
Carozza A, 2001, TEX HEART I J, V28, P96
[9]   Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid [J].
Craig, WA .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :479-+
[10]   CONTINUOUS INFUSION OF BETA-LACTAM ANTIBIOTICS [J].
CRAIG, WA ;
EBERT, SC .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (12) :2577-2583